


Synergy between Tubacin and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
Tubacin
Tubacin + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 24



A = MM1S Cells, B = RPMI Cells

Fig. 30



Synergy between NKI-94-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0. 1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0. 1
1
10
100
Concentration (in uM)
NKI-94-1
NKI-94-1 + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 33



Synergy between NKI-59-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
NKI-59-1
NKI-59-1 + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 36



Synergy between NKI-82-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.01
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
NKI-82-1
NKI-82-1 + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 42




Synergy between NKI-84-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.01
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
NKI-84-1
NKI-84-1 + 5 nM Velc
A = MM1S Cells, B = RPMI Cells

Fig. 45

Effect of Tubacin and NK-84 on Tubulin Acetylation



IB: anti-AcTub

48/72

RPMI-8226

Fig. 47




Fig. 53B



Synergy between Tubacin and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
Tubacin
Tubacin + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 24



NKI-8T-1 Cytotoxicity
A
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
A = MM1S Cells, B = RPMI Cells

Fig. 30



Synergy between NKI-94-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0. 1
1
10
100
Concentration (in uM)
B
100
60
20
%Viability
0. 1
1
10
100
Concentration (in uM)
NKI-94-1
NKI-94-1 + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 33



Synergy between NKI-59-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
NKI-59-1
NKI-59-1 + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 36



Synergy between NKI-82-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.01
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
NKI-82-1
NKI-82-1 + 5 nM Velcade
A = MM1S Cells, B = RPMI Cells

Fig. 42



Synergy between NKI-84-1 and Velcade in Myeloma Cells
A
100
60
20
0
%Viability
0.01
0.1
1
10
100
Concentration (in uM)
B
100
60
20
0
%Viability
0.1
1
10
100
Concentration (in uM)
NKI-84-1
NKI-84-1 + 5 nM Velc
A = MM1S Cells, B = RPMI Cells

Fig. 45



Effect of Tubacin and NK-84 on Tubulin Acetylation
DMSO
Tubacin
NK-84
.03 .1 .3 1 3 10 .03 .1 .3 1 3 10
IB: anti-AcTub
RPMI-8226

Fig. 47



NKI-201-1
NKI-233-1
NKI-235-1
NKI-234-1
NKI-207-1
NKI-236-1
NKI-208-1
OMe
OMe

Fig. 53B